FindTrial
Sign In

short course antiseisure medication in children & adolescent (low risk subgroup) with single calcified brain NCC

Early antiseizure medication tapering in children and adolescents aged 2-18 years with single calcified parenchymal neurocysticercosis in a low-risk subgroup identified by risk assessment: a single arm intervention study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/040197
Enrollment
30
Registered
2022-02-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B699- Cysticercosis, unspecified

Interventions

Intervention1: 1.identify a low-risk group by risk assessment based on clinical, EEG, and MRI brain parameters which has low probability of seizure recurrence 2.early tapering of ASM in the low-risk g

Sponsors

All India Institute of Medical Science New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a) Children and adolescents aged 2-18 years with single parenchymal calcified or granular NCC with follow up from viable NCC stage b) Seizure free on ASM for 6-9 months or12-15 months C) resolving or calcified NCC @ 6 month CECT

Exclusion criteria

Exclusion criteria: h/o status epilepticus requiring hospitalization three or more episodes of seizures after starting ASM significant perilesional edema ( 2 times the size of calcified focus or any size of perilesional edema with calcified focus >1 cm. any other brain pathogy ( hippocampal sclerosis, vascular malmormation, old insult sequale)

Design outcomes

Primary

MeasureTime frame
a)to identify a low-risk group by risk assessment based on clinical, EEG, and MRI brain parameters which has low probability of seizure recurrence, and b)to estimate the incidence of staying seizure free after early tapering of ASM in the low-risk group with follow up duration of at least 6 months Timepoint: 6 months after stopping ASM—

Secondary

MeasureTime frame
a) to estimate the association of MRI brain parameters with seizure recurrence in the low-risk group after early tapering of ASM with follow up duration of at least 6 months b) to estimate the association of clinical, EEG and MRI brain parameters with seizure recurrence in patients not included in the low-risk group and on ASM therapy during the study period Timepoint: follow up duration at least 6 months—

Countries

India

Contacts

Public ContactDr Biswaroop Chakrabarty

AIIMS New Delhi

biswaroopchakrabarty@gmail.com9818260603

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026